Harvard Bioscience Earnings Call Transcripts
Fiscal Year 2026
-
Leadership and board have been refreshed, with a strategic focus on translational science and operational consolidation. Financial guidance targets improved margins and recurring revenue, driven by new product innovation and expanding pharma/biotech sales. Project Viking and debt restructuring are expected to yield significant cost savings and support future growth.
-
Q1 2026 revenue was $20.8M with a 59% adjusted gross margin, driven by new product growth and higher pharma/biotech sales. Guidance for 2026 is reaffirmed, with expected revenue growth of 2%-4% and margin expansion, while Project Viking and new initiatives support long-term profitability.
-
Leadership is focused on innovation and operational efficiency, targeting high-growth areas like organoids and bioproduction. Financials are strong with improved margins, reduced debt service, and new products expected to double their revenue share. Academic, pharma, and CRO markets are key segments, with Asia showing recovery.
-
Stockholders approved both the reverse stock split amendment and the adjournment proposal with over 97% support. Final results will be published in a Form 8-K, and any submitted questions will be answered separately.
Fiscal Year 2025
-
2025 saw foundational restructuring, improved margins, and a strategic pivot to translational science. Despite revenue declines from tariffs and NIH delays, cost actions drove EBITDA growth. 2026 guidance calls for modest revenue and margin gains, with NPI and Asia Pacific recovery supporting growth.
-
Revenue reached $20.6M with improved gross margin and adjusted EBITDA, supported by cost reductions and strong product demand. Q4 guidance anticipates $22.5–$24.5M revenue, with risks from potential NIH funding delays due to a government shutdown.
-
Q2 2025 revenue was $20.5M, above guidance but down year-over-year, with gross margin at 56.4%. Cost reductions improved adjusted EBITDA and cash flow, while macro risks from NIH funding and tariffs persist. Q3 guidance is $19–$21M revenue and 56%–58% margin.
-
Q1 2025 revenue and gross margin declined year-over-year, with a $48M goodwill impairment driving a large operating loss. Cash flow improved, and net debt was reduced. New product launches and regulatory trends support future growth, but uncertainty in NIH funding and China tariffs weigh on the outlook.
-
Revenue reached $94 million in 2024 with a focus on recurring business and lean operations. New product launches in electroporation, organoids, and shared animal housing are driving growth, while expanded distribution and industry tailwinds are expected to offset NIH-related headwinds.
-
Operational consolidation and cost control have led to industry-leading margins, with preclinical systems now the main growth driver. Organoid and telemetry innovations are expected to deliver double-digit to 50%+ growth, while high operating leverage positions the business for rapid value creation as macro headwinds ease.
-
The company is shifting focus toward industrial and pharmaceutical customers, driving growth through innovative technologies like organoid testing and bioproduction tools. Recent operational improvements and new product launches are expected to fuel double-digit growth and recurring revenues in 2025.
Fiscal Year 2024
-
Q4 revenue declined 13% year-over-year but improved sequentially, with gross margin stable near 57%. New product launches in telemetry, bioproduction, and organoid platforms are driving growth, while refinancing is required after a covenant breach.
-
Q3 revenue declined 13% year-over-year to $22M, with stabilization in Americas and Europe but continued weakness in China/APAC. Gross margin remained strong at 58.1%, and cost reductions plus new product launches are expected to drive improved profitability and growth in Q4 and 2025.
-
The presentation highlighted a strategic shift toward industrial customers, robust product innovation, and a focus on recurring revenue. Despite macroeconomic headwinds, new technologies and expanding bioproduction capabilities are expected to drive double-digit growth and margin improvement.
-
Q2 2024 saw revenue decline 20% year-over-year amid global market headwinds, with gross margin holding at 57.2% and adjusted EBITDA down sharply. New product launches and cost reductions are expected to drive sequential growth and support a double-digit long-term growth target.
-
Advanced life science tools provider reported $112M revenue in 2023, with strong recurring revenue and improved margins. New product launches and APAC recovery are expected to drive growth in the second half, while innovations in organoid and bioproduction systems target high-value niches.